MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients

Por Navarro, Alfons, Muñoz, Carmen, Gaya, Anna, Díaz-Beyá, Marina, Gel, Bernat, Tejero, Rut, Díaz, Tania, Martinez, Antonio, Monzó, Mariano
Publicado em 2013

Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

Por Diaz, Tania, Navarro, Alfons, Ferrer, Gerardo, Gel, Bernat, Gaya, Anna, Artells, Rosa, Bellosillo, Beatriz, Garcia-Garcia, Mar, Serrano, Sergi, Martínez, Antonio, Monzo, Mariano
Publicado em 2011

PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma

Por Cordeiro, Anna, Navarro, Alfons, Gaya, Anna, Díaz-Beyá, Marina, Gonzalez-Farré, Blanca, Castellano, Joan Josep, Fuster, Dolors, Martínez, Carmen, Martínez, Antonio, Monzó, Mariano
Publicado no Oncotarget (2016)

Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy

Por Rovira, Jordina, Valera, Alexandra, Colomo, Lluis, Setoain, Xavier, Rodríguez, Sonia, Martínez-Trillos, Alejandra, Giné, Eva, Dlouhy, Ivan, Magnano, Laura, Gaya, Anna, Martínez, Daniel, Martínez, Antonio, Campo, Elías, López-Guillermo, Armando
Publicado no Ann Hematol (2014)